Ma Dodd

Direct health care costs of 4 common skin ulcers in New Mexico Medicaid fee-for-service patients.

OBJECTIVE:To determine health care costs associated with pressure ulcers, ulcers of the lower limbs, other chronic ulcers, and venous leg ulcers from the New Mexico Medicaid fee-for-service program perspective. DESIGN:Retrospective analysis of claims database MAIN OUTCOME MEASURES:Physician visit, hospital, and prescription costs were determined for New Mexico Medicaid patients with a primary and/or secondary diagnosis of 1 of 4 identified categories of skin ulcers from January 1, 1994, through December 31, 1998. Costs were determined in terms of mean and median annual cost per patient and total costs per year. Zero dollar claims were included within the cost calculations. All costs are expressed in 2000-dollar values. MAIN RESULTS: Mean annual physician visit costs per patient ranged from

Position statement on interdisciplinary team training in geriatrics: An essential component of quality health care for older adults

71 (standard deviation [SD] =

Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model

60) for venous leg ulcers in 1998 to

PDB9 PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS

520 (SD =

Agreement between self-report and prescription data in medical records for pregnant women†‡§

1228) for pressure ulcers in 1996. Mean annual hospital costs per patient ranged from

Minocycline-Associated Tooth Staining

266 (SD =

PHP71 IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE

348) for other chronic ulcers in 1998 to

DB4 STRESS AND COPING STRATEGIES ASSOCIATED WITH PHYSICAL AND MENTAL HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

15,760 (SD =

PRP11: CHANGES IN ASTHMA-RELATED HEALTHCARE UTILIZATION AND COSTS AFTER THE ADDITION OF SALMETEROL TO A MEDICAID POPULATION

30,706) for pressure ulcers in 1998. Mean annual prescription costs per patient ranged from

PMH41 REDUCTION IN LONG-ACTING BENZODIAZEPINE THERAPY AND ASSOCIATED FRACTURES IN ELDERLY MEDICAID PATIENTS

145 (SD =